Risk of cardiovascular events associated with selective COX-2 inhibitors.

By D. Mukherjee, S. Nissen, Eric J. Topol. Journal of the American Medical Association (JAMA), 2001

1,859 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/7a377f62af8909f715570b30a16de2ffdb5210f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. P. Rao
2. E. Knaus

Citations in the corpus

• Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. (2014, neutral): “Other NSAIDs Rofecoxib was introduced to the market shortly after the first COXIB, celecoxib.”
• Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “Whether COX-2 inhibition presents a risk for thrombotic events requires further study (Mukherjee et al., 2001a).”
• Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “were raised regarding their adverse cardiovascular events (16).”